IPM Take
Cardiology has spent years learning not to dismiss erectile dysfunction as a problem confined to sexual health.
The Princeton IV consensus describes ED as a cardiovascular risk marker and risk-enhancing factor, reflecting its association with endothelial dysfunction, atherosclerosis and later cardiovascular events. New UK data now raise a broader possibility: the vascular signal associated with ED may extend beyond the coronary circulation to the eye.
In two large primary-care datasets, prescriptions for ED medication were associated with higher odds of primary open-angle glaucoma. The study does not establish that PDE5 inhibitors cause glaucoma, and it does not justify routine ophthalmic screening of every patient with ED. But its scale and consistency strengthen an emerging question for personalised prevention: when one vascular bed starts signalling dysfunction, how narrowly should medicine look?
Executive Summary
A prospective nested case-control study published in the British Journal of Ophthalmology examined the relationship between erectile dysfunction and primary open-angle glaucoma using nationally representative UK primary-care data.
Researchers identified 218,056 men with primary open-angle glaucoma and matched them by age and general practice to 876,872 controls without glaucoma diagnosis or treatment. ED medications had been prescribed to 20% of glaucoma cases compared with 17% of controls.
After adjustment for age, ethnicity and deprivation, ED medication use remained associated with higher odds of primary open-angle glaucoma in both databases analysed. The odds ratio was 1.29 in CPRD Gold and 1.17 in CPRD Aurum. Hypertension and diabetes were also associated with increased glaucoma risk.
Importantly, the investigators did not interpret the findings simply as a medication safety signal. Because ED medicines are commonly used intermittently, they argued that the association may be more consistent with a shared vascular pathway linking erectile dysfunction and glaucoma, although experimental studies are needed before causal conclusions can be drawn.
Why it matters
- HTA bodies: There is no immediate HTA implication, but the findings illustrate why outcomes outside traditional cardiovascular endpoints may become relevant when evaluating interventions that affect vascular physiology across multiple organ systems.
- Payers: The study does not support a new screening mandate. If subsequent research confirms a meaningful vascular link, however, targeted eye-health assessment in selected high-risk men could eventually become part of more integrated cardiovascular prevention pathways.
- Industry / innovation partners: The findings highlight an opportunity for risk-stratification models that move beyond disease silos. Vascular phenotyping incorporating sexual, cardiovascular, metabolic and ocular indicators could become increasingly relevant to personalised prevention.
Erectile dysfunction has gradually moved from the margins of cardiovascular medicine toward the centre of risk assessment.
That shift has been driven by a growing body of evidence showing that ED often shares the same vascular biology as cardiovascular disease. Endothelial dysfunction, hypertension, diabetes, dyslipidaemia and atherosclerosis all intersect with erectile function, and ED symptoms can precede clinically evident cardiovascular disease.
The Princeton IV consensus therefore recommends treating ED as a cardiovascular risk-enhancing factor, with cardiovascular risk assessment and, in selected men, coronary artery calcium scoring considered to uncover subclinical disease.
A new UK study suggests that this vascular story may extend to another organ.
Researchers used data from the Clinical Practice Research Datalink, analysing more than one million men across two large UK primary-care datasets. They compared 218,056 men diagnosed with primary open-angle glaucoma with 876,872 matched controls.
Prescriptions for erectile-dysfunction medication were more common among men who developed glaucoma.
In the CPRD Gold database, ED medication use was associated with 29% higher odds of primary open-angle glaucoma. In the larger CPRD Aurum dataset, the increase was 17%. The association persisted after adjustment for age, ethnicity and socioeconomic deprivation.
The obvious interpretation might be that the drugs themselves are responsible.
But that conclusion is far from established.
PDE5 inhibitors such as sildenafil and tadalafil are vasoactive medicines, so a pharmacological explanation cannot simply be excluded. Indeed, a separate multinational observational study published this year found that long-term tadalafil use for lower urinary tract symptoms was associated with a 22% higher risk of glaucoma over five years and a 33% higher risk of primary open-angle glaucoma specifically.
Yet the new UK researchers point to another possibility.
ED medication is frequently taken intermittently rather than continuously. If the drug exposure itself were the main driver, a straightforward dose-related medication effect might be expected. Instead, the authors argue that treatment for ED may be functioning partly as a marker for the vascular dysfunction underlying ED itself.
That hypothesis matters for cardiology because primary open-angle glaucoma is increasingly being investigated not only as a problem of intraocular pressure but also through vascular mechanisms involving ocular perfusion and microvascular regulation.
In other words, the penis, coronary circulation and optic nerve may appear to belong to different specialties, but they all depend on healthy vascular function.
The study cannot establish that a shared vascular mechanism causes both diseases. Observational primary-care data remain vulnerable to residual confounding, prescription records do not establish actual medication use, and men treated for ED may differ from untreated men in ways that healthcare databases cannot fully capture. The authors explicitly call for experimental work before the relationship can be interpreted causally.
Nor should the study be interpreted as evidence that men should stop PDE5 inhibitors. Current cardiovascular guidance considers these medicines generally safe for appropriate patients with cardiovascular disease, while recognising important contraindications such as concurrent nitrate therapy.
The more interesting signal is therefore not a new reason to fear ED medication.
It is another reason to stop thinking about erectile dysfunction in isolation.
A symptom that may precede coronary disease could also be pointing toward wider systemic vascular vulnerability. Whether glaucoma eventually becomes part of that risk conversation remains uncertain.
But the boundaries between sexual health, cardiology and ophthalmology are beginning to look increasingly artificial.
